Literature DB >> 23756783

Increased carotid intima media thickness is associated with prolactin levels in subjects with untreated prolactinoma: a pilot study.

Xiao-Bing Jiang1, Cui-Ling Li, Dong-Sheng He, Zhi-Gang Mao, Dong-Hong Liu, Xiang Fan, Bin Hu, Yong-Hong Zhu, Hai-Jun Wang.   

Abstract

Hyperprolactinemia is associated with endothelial dysfunction and atherogenic risk factors, but carotid intima media thickness (IMT) has not been studied in hyperprolactinemic patients. To determine whether untreated hyperprolactinemia contributes to increased carotid IMT. Thirty-one prolactinoma patients and 60 healthy controls were respectively studied. Participants underwent hormone evaluation. Anthropometric parameters (body mass index and blood pressure), inflammatory markers (high-sensitivity C-reactive protein and fibrinogen), serum glucose, insulin, lipid and apolipoprotein profiles were also determined. Endothelial function measured as the flow-mediated dilation (FMD) of a brachial artery and carotid IMT were evaluated using high-resolution ultrasonography. Multivariate linear regression analysis was applied to identify independent determinants of FMD and carotid IMT. Triglycerides, homeostasis model assessment of insulin resistance, apolipoprotein (apo)B/apoA-I ratio, high-sensitivity C-reactive protein (hsCRP) and fibrinogen were significantly higher, while apoA-I was significantly lower in patients with prolactinomas than in the controls. Meanwhile, decreased FMD and increased carotid IMT were observed in hyperprolactinemic group. Serum prolactin was positively correlated with triglycerides, apoB/apoA-I ratio, hypogonadal, hsCRP and fibrinogen (P < 0.05), but inversely associated with apoA-I and HDL-C (P ≤ 0.001). Moreover, prolactin was found negatively correlated with FMD (r = -0.576, P < 0.0001), and positively correlated with mean carotid IMT (r = 0.652, P < 0.0001). Multivariate regression analysis revealed that prolactin determined, independent of traditional risk factors, FMD (B = -0.589, 95% confidence interval (CI) -2.525 to -0.804, P = 0.001) and mean carotid IMT (B = 0.527, 95% CI 0.027-0.069, P < 0.0001). Hyperprolactinemia may be involved in the preclinical increase in carotid IMT, directly or by promoting atherogenic factors, including insulin resistance, low-grade inflammation and endothelial dysfunction. Additional studies are warranted to confirm our findings and explore the mechanisms underlying prolactin-associated early atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23756783     DOI: 10.1007/s11102-013-0495-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  29 in total

1.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

2.  Structural and functional effects of high prolactin levels on injured endothelial cells: evidence for an endothelial prolactin receptor.

Authors:  C J Merkle; L A Schuler; R C Schaeffer; J M Gribbon; D W Montgomery
Journal:  Endocrine       Date:  2000-08       Impact factor: 3.633

3.  Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.

Authors:  Juan Jesús Carrero; John Kyriazis; Alper Sonmez; Ioannis Tzanakis; Abdul Rashid Qureshi; Peter Stenvinkel; Mutlu Saglam; Kostas Stylianou; Halil Yaman; Abdullah Taslipinar; Abdulgaffar Vural; Mahmut Gok; Mujdat Yenicesu; Eugene Daphnis; Mahmut Ilker Yilmaz
Journal:  Clin J Am Soc Nephrol       Date:  2011-12-22       Impact factor: 8.237

4.  BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists.

Authors:  Cintia M dos Santos Silva; Flavia R P Barbosa; Giovanna A B Lima; Leila Warszawski; Rosita Fontes; Romeu C Domingues; Mõnica R Gadelha
Journal:  Obesity (Silver Spring)       Date:  2010-06-17       Impact factor: 5.002

5.  Dual effects of hyperprolactinemia on carrageenan-induced inflammatory paw edema in rats.

Authors:  Julieta E Ochoa-Amaya; Benjamin E Malucelli; Pablo E Cruz-Casallas; Antonia G Nasello; Luciano F Felicio; Maria I R Carvalho-Freitas
Journal:  Neuroimmunomodulation       Date:  2011-03-24       Impact factor: 2.492

6.  Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells.

Authors:  Pável Montes de Oca; Yazmín Macotela; Gabriel Nava; Fernando López-Barrera; Gonzalo Martínez de la Escalera; Carmen Clapp
Journal:  Lab Invest       Date:  2005-05       Impact factor: 5.662

7.  Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes.

Authors:  E M Dahlén; T Länne; J Engvall; T Lindström; E Grodzinsky; F H Nystrom; C J Ostgren
Journal:  Diabet Med       Date:  2009-04       Impact factor: 4.359

8.  Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors.

Authors:  George A Georgiopoulos; Kimon S Stamatelopoulos; Irene Lambrinoudaki; Maria Lykka; Katerina Kyrkou; Dimitrios Rizos; Maria Creatsa; George Christodoulakos; Maria Alevizaki; Petros P Sfikakis; Christos Papamichael
Journal:  Hypertension       Date:  2009-05-18       Impact factor: 10.190

9.  Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.

Authors:  Mirjana Doknic; Sandra Pekic; Milos Zarkovic; Milica Medic-Stojanoska; Carlos Dieguez; Felipe Casanueva; Vera Popovic
Journal:  Eur J Endocrinol       Date:  2002-07       Impact factor: 6.664

10.  Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study.

Authors:  Anne Q Reuwer; Brigitte M Sondermeijer; Suzanne Battjes; Rogier van Zijderveld; Danka J F Stuijver; Peter H Bisschop; Marcel Th B Twickler; Joost C M Meijers; Reinier O Schlingemann; Erik S Stroes
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

View more
  6 in total

Review 1.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

Review 2.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 3.  Coronary Microvascular Function and Beyond: The Crosstalk between Hormones, Cytokines, and Neurotransmitters.

Authors:  Carlo Dal Lin; Francesco Tona; Elena Osto
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

4.  The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.

Authors:  Robert Krysiak; Joanna Okrzesik; Boguslaw Okopien
Journal:  Endocrine       Date:  2014-09-20       Impact factor: 3.633

5.  Evaluation of atherosclerosis after cessation of cabergoline therapy in patients with prolactinoma.

Authors:  Berçem Ayçiçek Doğan; Ayşe Arduç; Mazhar Müslüm Tuna; Narin Imga Nasıroğlu; Serhat Işık; Dilek Berker; Serdar Güler
Journal:  Anatol J Cardiol       Date:  2015-07-29       Impact factor: 1.596

6.  The Association between Oligomenorrhea, Onset of Menopause and Metabolic Syndrome in Thai Postmenopausal Women.

Authors:  Siripen Ongsupharn; Tawiwan Pantasri; Worashorn Lattiwongsakorn; Nuntana Morakote
Journal:  J Menopausal Med       Date:  2018-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.